X

Drug Profile

NA 911

Alternative Names: NA-911

Latest Information Update: 21 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biomed Industries
Class Neuroprotectants; Small molecules; Vascular disorder therapies
Mechanism of Action Neurogenesis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Stroke

Most Recent Events

19 Aug 2024 Biomed Industries plans a phase-II trial for Stroke (PO),
19 Jun 2024 Pharmacokinetics and adverse events data from a phase IIb trial in Stroke released by Biomed Industries (Biomed Industries pipeline, June 2024)
06 May 2024 Phase-II clinical trials in Stroke (Prevention) in USA (unspecified route) prior to May 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com